EAST WINDSOR, NJ / ACCESSWIRE / February 28, 2017 / Men’s clothing company, Three Arrows Affiliated, has recently launched their crowdfunding campaign. Three Arrows is now live on Kickstarter raising funds for its new subscription based clothing line. Three Arrows and their founder, Alec Goldberg, have created an innovative solution to take the hassle out of men’s shopping. By combining the three main lifestyle categories – casual wear, active wear, and career wear – into one subscription based service, Three Arrows is looking to simplify the shopping experience while providing top quality clothing at a competitive price.

The company stands out from others as Three Arrows allows customers to order kits, try them on at home, and return any unwanted items, for free. Consumers can choose to receive kits each month, every two months, or even every three months. Each lifestyle line (active, casual, career) offers various choices for consumers to choose from. If you have a busy lifestyle and can’t take the time to pick out clothing each month, Three Arrows experts will do it for you.

Three Arrows solves menswear by rethinking methods of production, design, and distribution. This means first providing wearers with the highest quality technical apparel for every aspect of their lifestyle (Active, Social, and Career Wear). Three Arrows Affiliated began because there was no way to get the best clothes for every part of your lifestyle – whenever you want – without feeling you’re paying too much. Three Arrows is high quality, US-Made menswear for every part of your life on a platform that provides wearers with a comprehensive solution to all their apparel needs.

The three lifestyle categories Three Arrows is aiming to combine (Active Wear, Social Wear and Career Wear) will simplify the entire shopping experience. Active Wear is designed for superior performance for any of your workouts, training sessions, and multi-sport activities. As for Social Wear, the subtle style is designed to easily match other garments in and out of their collection. Finally, for Career Wear, they use lightweight fabrics that provide light form-fitting characteristics with excellent drapery. The cross-functionality of the garments enables them to be worn from the office, to a night out with friends. With technical features like gussets, hidden buttons, and reinforced collars, the Career Wear is truly made to work.

About Three Arrows

Founder and CEO, Alec Goldberg, started Three Arrows Affiliated because he wanted to be able to get the best clothes for every part of our lifestyle – whenever we wanted – without going broke. To do so would require providing not only the best clothes, but the best way of getting those clothes. So he, and his team, developed an all-in-1 apparel platform that provides affiliates the ability to control when they get clothes, how many clothes they get, and how much they want to spend. Most importantly, affiliates get to choose from a true Lifestyle apparel line consisting of high quality active-wear, social-wear, and career-wear.

Media Contact:

Jeremy Schulkin
609.752.4440
jeremy@jandecreative.com

https://www.kickstarter.com/projects/1873161147/three-arrows-affiliated?ref=nav_search

SOURCE: Three Arrows Affiliated

ReleaseID: 456189

Gains authorizations spanning more than 2,000 new distribution outlets throughout the US and Canada
First major Kombucha brand to become shelf-stable with greater than 9 months of shelf-life enabling expansion to all retail channels of distribution

DENVER, CO / ACCESSWIRE / February 28, 2017 / New Age Beverages Corporation (NASDAQ: NBEV) the Colorado-based Company that markets the brands XingTea®, Aspen Pure® Rocky Mountain Water, Búcha® Live Kombucha, Marley One Drop® Coffee, and Marley Mellow Mood® Relaxation Drinks, today announced the official launch of its Búcha® Live Kombucha brand that no longer requires refrigerated distribution or shelving yet still upholds its industry leading 9 months of shelf life while maintaining greater than 2 Billion live CFU’s (probiotics) per serving.

10 days ago, New Age Beverages Corporation completed a successful up-listing to the NASDAQ Capital Market Exchange together with a financing led by Aegis Capital and Maxim Group that raised more than $17 million. In addition, the Company has been expanding organically with the most recent reported comparable quarterly revenue growth of 11% vs. prior year. One of the drivers of the growth has been the Búcha® Live Kombucha brand, that has been growing in both distribution and same store sales growth since becoming part of the New Age portfolio.

New Age has long been a technological leader in the Kombucha segment with its proprietary production process that leads to no vinegar-like aftertaste, and no secondary fermentation, carbonation or sugar production after bottling. Now, coupled with its 9 months of shelf-life vs. a 90-day average for most other kombuchas, the product has evolved to become fully shelf-stable with no requirements for refrigeration until opened. New Age has been able to achieve shelf-stability with no deterioration to the more than 2 Billion CFU’s (Colony Forming Units/Probiotics) at production and no degradation to its consumer preferred taste profile.

The move to shelf-stability opens the brand up to delivery across all channels of distribution throughout North America and internationally. As a result, the Búcha® Live Kombucha Brand has recently gained authorizations for distribution from major regional and national retailers spanning more than 2,000 stores, including major national and regional Texas-based grocery retailers, major regional East Coast grocery retailers, and a major Canadian convenience store operator. These new commitments have all been gained in the past 30 days, and will be rolling out to all committed stores over the next few months.

Brent Willis, Chief Executive Officer of New Age Beverages commented, “We were very pleased to have completed the uplist to the NASDAQ and financial raise with some truly world-class long-term financial partners just weeks ago. However, continuing our momentum of organic growth is what really matters and what will drive returns for all our shareholders in the long-term. Leveraging technological points of difference to gain these wins is extremely gratifying, and we believe we are just at the tip of iceberg with what we have in front of us.”

About New Age Beverages Corporation (NASDAQ: NBEV)

New Age Beverages Corporation is a Colorado-based, healthy functional beverage company originally founded in 2003 and re-created via the combination of XingTea®, Aspen Pure® Rocky Mountain Water, Búcha® Live Kombucha, and New Age Beverages in June 2016. In October 2016, the Company signed a management agreement to take over the Marley One Drop® RTD Coffee, and Marley Mellow Mood™ Relaxation Drinks brands. The Company competes in the fast growing healthy functional beverage segments including Ready to Drink (RTD) Tea, RTD Coffee, Kombucha, Energy Drinks, Relaxation Drinks and Functional Waters. The Company’s brands are sold across all 50 states within the US and in more than 10 countries internationally across all channels via direct and store door distribution systems. The company operates the websites www.newagebev.us, www.mybucha.com, www.xingtea.com, www.aspenpure.com, and www.drinkmarley.com.

Safe Harbor Disclosure

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are any statement reflecting management’s current expectations regarding future results of operations, economic performance, financial condition and achievements of the Company including statements regarding New Age Beverage’s expectation to see continued growth. The forward-looking statements are based on the assumption that operating performance and results will continue in line with historical results. Management believes these assumptions to be reasonable but there is no assurance that they will prove to be accurate. Forward-looking statements, specifically those concerning future performance are subject to certain risks and uncertainties, and actual results may differ materially. New Age Beverages competes in a rapidly growing and transforming industry, and other factors disclosed in the Company’s filings with the Securities and Exchange Commission might affect the Company’s operations. Unless required by applicable law, New Age Beverages undertakes no obligation to update or revise any forward-looking statements.

For investor inquiries about New Age Beverages Corporation please contact:

Amato and Partners, LLC
Investor Relations Counsel
admin@amatoandpartners.com

Websites:

www.newagebev.us
www.mybucha.com
www.xingtea.com
www.aspenpure.com
www.drinkmarley.com

SOURCE: New Age Beverages Corporation

ReleaseID: 456168

VANCOUVER, BC / ACCESSWIRE / February 28, 2017 / Tasca Resources Ltd. (“Tasca”, “TAC” or the “Company”) (TSX Venture: TAC) (Frankfurt: 3TA) is pleased to announce that it has completed the listing process of its common shares on the Frankfurt Stock Exchange and is now trading under the symbol “3TA” on the Quotation Board of the Frankfurt Stock Exchange, also known as Börse Frankfurt (FWB). The market maker representing Tasca in Germany is Bankhaus Scheich Wertpapierspezialist AG, licensed specialist at the Börse Frankfurt.

The listing of Tasca’s shares on the Frankfurt Stock Exchange is anticipated to broaden the Company’s shareholder base in Europe and increase trading activity in its shares, while at the same time facilitating investment in Tasca by the European investing community. Tasca will maintain its primary listing on the TSX Venture Exchange.

The Frankfurt Stock Exchange is the world’s third largest organized exchange-trading market in terms of turnover and dealings in securities. Only the NASDAQ and the New York Stock Exchanges are larger. The electronic trading platform of the Frankfurt Stock Exchange, XETRA, has made it the world’s second-largest fully electronic cash market.

Tasca believes the Frankfurt listing marks another step forward for the Company in creating more liquidity and increase market awareness for its shareholders.

Tasca CEO Clive Massey stated, “Listing Tasca on the Frankfurt Stock Exchange as well as the TSX Venture Exchange will give the Company exposure to a much larger potential investor base. We feel this is a great opportunity for Tasca to introduce the Company and its Bleiberg Property to a receptive European investing audience.”

About Tasca

Tasca Resources Ltd. is a Canadian based mining company that is focused on acquiring properties through strategic joint ventures and property acquisitions. Tasca has signed a Property Option Agreement to acquire the Bleiberg zinc-lead-germanium-fluorite project, located in southern Austria, west of the city of Villach. The Bleiberg Property consists of 116 mining concessions in the land registry municipalities of Bad Bleiberg, Nötsch im Gailtal, St. Stefan im Gailtal and Paternion in southwestern Austria. The Bleiberg Property hosts an extensive mining infrastructure with more than 1150 kilometres of tunnels and 3 mine shafts. Historic production was about 500,000 tons per year, and it was one of the 6 largest Germanium producers in the world while it was in production. Mineralization consists of stratabound galena and sphalerite within Triassic limestones and intercalated carbonates. The sphalerite also carries average values of 200 parts per million germanium and 2000 parts per million cadmium. The historically mined mineralized bodies were stratiform zones ranging from 1 metre thick and 100 metres in diameter to 5 metres thick and several hundred metres in diameter.

For additional information regarding the above noted property and other corporate information, please visit the Company’s website at www.tascaresources.com

ON BEHALF OF THE BOARD OF DIRECTORS

“Clive Massey”

Clive H. Massey
President & CEO

For further information, please contact:

Tasca Investor Relations
Phone: (604) 644-6794
Email: tascaresources@gmail.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains certain statements that may be deemed “forward-looking” statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Tasca Resources Ltd. believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward looking statements are based on the beliefs, estimates and opinions of Tasca Resources Ltd. management on the date the statements are made. Except as required by law, Tasca Resources Ltd. undertakes no obligation to update these forward-looking statements in the event that management’s beliefs, estimates or opinions, or other factors, should change.

SOURCE: Tasca Resources Ltd.

ReleaseID: 456128

NEW YORK, NY / ACCESSWIRE / February 28, 2017 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued an update on Propanc Health Group Corp (OTCQB: PPCH).

The report is available here: PPCH February 2017 Update Note.

Propanc is an Australian-based biotechnology company seeking to develop new long term treatments for cancer. The company’s research and development activities have been focused on anti-cancer compounds targeting cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers. Propanc’s formulation of anti-cancer compounds utilizes pro-enzyme therapy. Its lead drug candidate, PRP, is a patented formulation consisting of two proenzymes, trypsinogen (T) & chymotrypsinogen (C) from bovine pancreas. PRP targets malignant cancer cells through multiple pathways, which the company believes may create a lasting clinical benefit for the patient. Propanc is currently completing non-clinical studies and intends to undertake Phase I, II and III clinical trials to assess the safety and efficacy of their product in specific patient populations. The company has also stated that it is pursuing strategic partners in the industry, and that it hopes to have meaningful discussions with potential partners following the release of new data.

Additional highlights from the update note are as follows:

Propanc CEO provides positive investor update

Propanc CEO, James Nathanielsz provided a detailed investor update in January, highlighting accomplishments by the company in 2016 and outlining its clinical plans as the company seeks to begin a Phase 1 human study by the end of 2017. Key accomplishments during 2016 included a successful scientific advice meeting with the Medicines and Healthcare Products Regulatory Agency, MHRA, in the UK, during which the company defined the non-clinical and clinical development pathway for PRP. Other accomplishments included developing an enzyme linked immunosorbent assay (ELISA) method, executing a manufacturing agreement with Belgium-based AmatsiQBiologicals, and developing a new infrared dye-labelled detection method for trypsinogen and chymotrypsinogen, the proenzymes used in PRP.

Propanc receives US patent allowance

Importantly Propanc has made progress advancing its intellectual property protection. The company submitted four new patents in the US, Australia and Spain, during 2016, relating to dosage and mechanism of action for its two proenzymes used in PRP, two proenzymes, trypsinogen (T) & chymotrypsinogen (C). Importantly, in January, Propanc received a notification of allowance from the US Patent Office providing coverage for a method of treating a solid tumor through administering a pharmaceutical composition comprising a therapeutically effective amount of trypsinogen and chymotrypsinogen to patients, a noteworthy accomplishment.

Low dose group 28-day GLP-compliant toxicity study complete

Looking ahead to 2017, Propanc is quickly moving to initiate a Phase 1 clinical trial for PRP by the end of the year. The company took a step in that direction recently, with the announcement that it had successfully completed the low dose group for its GLP-compliant 28-day repeat dose toxicity study. With no safety concerns in the low dose group, Propanc received approval to proceed with the middle and high dose groups from the International Animal Care & Use Committee (IACUC) in Melbourne, Australia.

Updating price target to $0.05 for PPHC

We are updating our price target to $0.05 for PPCH. This reflects the increase in shares since our initial valuation of the company in 2015 and continued capital needs, offset by the large opportunity targeted by the company with new potential therapies for pancreatic, ovarian and colorectal cancer. We continue to see Propanc as an intriguing microcap biotechnology company with a pre-clinical therapeutic pipeline targeting end markets with multi-billion dollar potential if the company can show efficacy in clinical trials and execute on a partner-based strategy for regulatory approval and commercialization.

Please review important disclosures on our website at www.seethruequity.com.

About Propanc Health Group Corporation

Propanc is developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. We have developed a formulation of anti-cancer compounds, which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Our products involve or employ pancreatic proenzymes, which are inactive precursors of enzymes. In the near term, we intend to target patients with limited remaining therapeutic options for the treatment of solid tumors. In future, we intend to develop our lead product to treat (i) early stage cancer and (ii) pre-cancerous diseases and (iii) as a preventative measure for patients at risk of developing cancer based on genetic screening. www.Propanc.com.

About SeeThruEquity

Since its founding in 2011, SeeThruEquity has been committed to its core mission: providing impactful, high quality research on underfollowed smallcap and microcap equities. SeeThruEquity has pioneered an innovative business model for equity research that is not paid for and is unbiased. SeeThruEquity is the host of acclaimed investor conferences that are the ultimate event for publicly traded companies with market capitalizations less than $1 billion.

SeeThruEquity is approved to contribute its research reports and estimates to Thomson One Analytics (First Call), the leading estimates platform on Wall Street, as well as Capital IQ and FactSet. SeeThruEquity maintains one of the industry’s most extensive databases of opt-in institutional and high net worth investors. The firm is headquartered in Midtown Manhattan in New York City.

For more information visit www.seethruequity.com.

Contact:

Ajay Tandon
SeeThruEquity
info@seethruequity.com

SOURCE: SeeThruEquity

ReleaseID: 456158

MINNEAPOLIS, MN / ACCESSWIRE / February 28, 2017 / Insignia Systems, Inc. (Nasdaq: ISIG) (“Insignia”) previously announced that it will issue its financial results for the fourth quarter and full year ended December 31, 2016, on Friday, March 3, 2017. Insignia also announced today that Insignia’s management team will host a conference call at 8:45 am ET/7:45 am CT that day to discuss these results. Interested parties may participate in the call by dialing (201) 689-8029 or toll-free (877) 407-8029. Please call in 10 minutes before the conference call is scheduled to begin and ask for the Insignia call.

A slide presentation and a link to the webcast of the conference call will be posted on the Investor Relations section of our website at www.insigniasystems.com. A replay of the conference call will be available for approximately 90 days by accessing the same link on our website. Please go to the website 15 minutes early to download and install any necessary audio software. We suggest listeners use Microsoft Explorer as their browser.

About Insignia Systems, Inc.

Insignia Systems, Inc. is a developer and marketer of innovative in-store products, programs and services that help consumer goods manufacturers and retail partners drive sales at the point of purchase. Insignia provides at-shelf media solutions in approximately 13,000 retail supermarkets, 2,000 mass merchants and 8,000 dollar stores. With a client list of over 200 major consumer goods manufacturers, including General Mills, Kellogg Company, Kraft Foods, Nestlé and P&G, Insignia helps major brands deliver on their key engagement, promotion, and advertising objectives right at the point-of-purchase. For additional information, contact (800) 874-4648, or visit the Insignia website at www.insigniasystems.com.

SOURCE: Insignia Systems, Inc.

ReleaseID: 456190

TORONTO, ON / ACCESSWIRE / February 28, 2017 / Stans Energy Corp. (TSX-V: HRE, OTC: HREEF), (“Stans” or the “Company”) informs its shareholders of a recent favourable decision by the Ontario Superior Court of Justice (the “Court”) to recognize the UNICTRAL Arbitral Award (the “Award”) of Entes Industrial Plans Construction & Erection Contracting Co. Inc. (“Entes”) against the Republic of Kyrgyzstan (the “Republic”).

In Entes v. Kyrgyz Republic, the Court recognized an international arbitral award for more than $22 million, which was granted in favour of Entes in 2015 by UNCITRAL Arbitral Tribunal on November 2016. The court found that to not grant recognition of the Award, the Award “must fundamentally offend the most basic and explicit principles of justice and fairness in Ontario or evidence intolerable ignorance or corruption on the part of the Arbitral Tribunal…. Examples of public policy grounds for refusing to enforce an arbitral award are fraud, corruption, bribery and similar serious cases…” stated Justice Conway in her decision.

Rodney Irwin, Stans CEO and President states, “Stans is eager to commence the merits phase of its’ UNCITRAL Tribunal to pursue a final and binding decision against the Kyrgyz Republic. The comments by the Ontario Court of Justice and other legal experts reassure management of the solid foundation of pursuing damages against the Republic before the UNCITRAL Tribunal. This is especially now evident when it comes to seeking recognition of UNICITRAL awards in Canada.”

In an article published on February 23, 2017, K. McCrystal and C. Chaisson comment, “the [Entes] decision confirms the Canadian courts’ adherence to the mandatory nature of the enforcement provisions in the UNCITRAL Model Law and New York Convention….Without clear evidence of one of the narrow grounds for refusing enforcement under Article 36 of the UNCTRAL Model Law, the Canadian courts will recognize and enforce international arbitral awards as court judgments. This deference to the arbitral process safeguards the finality of a tribunal’s decision and ensures that arbitral creditors can take advantage of the wide range of execution remedies available to judgment creditors.”

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

About Stans Energy

Stans Energy Corp. is a resource development company focused on advancing rare and specialty metals properties and processing technologies Stans is now transitioning into a supplier of materials and technologies that will assist in satisfying the future energy supply, storage and transmission needs of the world. Previously, the Company acquired, among other things, the right to mine the past producing rare earth mine, Kutessay II, in the Kyrgyz Republic Due to the expropriation actions taken by the Government of the Kyrgyz Republic, the Company is undertaking international arbitration litigation to protect the Company’s rights and recover damages estimated at over US$210,000,000, caused by the Republic.

We seek safe harbour.

Contact Details

Rodney Irwin
Stans Energy Corp
Interim President & CEO
rodney@stansenergy.com
647-426-1865

David Vinokurov
Stans Energy Corp
VP Corporate Development
david@stansenergy.com
647-426-1865

FORWARD LOOKING STATEMENTS: This document includes forward-looking statements as well as historical information. Forward-looking statements include, but are not limited to, use of proceeds from the Offering, the completion of the Offering, the continued advancement of the company’s general business development, research development and the company’s development of mineral exploration projects. When used in this press release, the words “will”, “shall”, “anticipate”, “believe”, “estimate”, “expect”, “intent”, “may”, “project”, “plan”, “should” and similar expressions may identify forward-looking statements. Although Stans Energy Corp. believes that their expectations reflected in these forward looking statements are reasonable, such statements involve risks and uncertainties and no assurance can be given that actual results will be consistent with these forward-looking statement. Important factors that could cause actual results to differ from these forward-looking statements include the potential that fluctuations in the marketplace for the sale of minerals, the inability to implement corporate strategies, the ability to obtain financing and other risks disclosed in our filings made with Canadian Securities Regulators.

Nov 16/2016 OSCJ Ruling

http://www.internationallawoffice.com/Newsletters/Arbitration-ADR/Canada/Borden-Ladner-Gervais-LLP/Ontario-court-recognises-arbitral-award-and-confirms-narrow-scope-of-public-policy-defence#

SOURCE: Stans Energy Corp.

ReleaseID: 456193

LONDON, UK / ACCESSWIRE / February 28, 2017 / Active Wall St. announces the list of stocks for today’s research reports. Pre-market the Active Wall St. team provides the technical coverage impacting selected stocks trading on the Toronto Exchange and belonging under the Consumer Defensive sector/ Education industry. Companies recently under review include CIBT Education Group, BrightPath Early Learning, and Bluedrop Performance Learning. Get all of our free research reports by signing up at:

http://www.activewallst.com/register/

On Monday, February 27, 2017, the Toronto Exchange Composite Index was down 0.45%, finishing the day at 15,463.51. The TSX Venture Composite Index, on the other hand, closed at 827.21, down 1.08%.

Active Wall St. has initiated research reports on the following equities: CIBT Education Group Inc. (TSX: MBA), BrightPath Early Learning Inc. (TSX-V: BPE), and Bluedrop Performance Learning Inc. (TSX-V: BPL). Register with us now for your free membership and research reports at:

http://www.activewallst.com/register/

CIBT Education Group Inc.

Vancouver, Canada headquartered CIBT Education Group Inc.’s stock finished Monday’s session flat at $0.67 with a total volume of 36,000 shares traded. Over the last three months and the previous one year, CIBT Education’s shares have surged 28.85% and 148.15%, respectively. The Company’s shares are trading above its 200-day moving average. CIBT Education’s 50-day moving average of $0.67 is above its 200-day moving average of $0.58. Shares of the Company, which through its subsidiaries, operates as an education and student-housing investment company, are trading at a PE ratio of 5.32. See our research report on MBA.TO at:

http://www.activewallst.com/register/

BrightPath Early Learning Inc.

On Monday, shares in Calgary, Canada-based BrightPath Early Learning Inc. recorded a trading volume of 114,000 shares, which was above their three months average volume of 66,642 shares. The stock ended the day 2.13% higher at $0.48. BrightPath Early Learning’s stock has gained 4.35% in the last one month and 60.00% in the previous one year. Shares of the Company, which provides child care services in Canada, are trading above its 50-day and 200-day moving averages. The stock’s 50-day moving average of $0.46 is above its 200-day moving average of $0.45. Register for free and access the latest research report on BPE.V at:

http://www.activewallst.com/register/

Bluedrop Performance Learning Inc.

On Monday, shares in St. John’s, Canada headquartered Bluedrop Performance Learning Inc. ended the session flat at $0.24 with a total volume of 144,456 shares traded. Bluedrop Performance Learning’s shares have surged 33.33% in the last three months and 166.67% in the previous one year. Shares of the Company are trading above its 200-day moving average. Further, the stock’s 50-day moving average of $0.26 is greater than its 200-day moving average of $0.21. Shares of Bluedrop Performance Learning, which designs, develops, and delivers workplace training for individuals, businesses, military personnel, and the public sector in Canada, are trading at a PE ratio of 24.00. Get free access to your research report on BPL.V at:

http://www.activewallst.com/register/

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 456163

CUPERTINO, CA / ACCESSWIRE / February 28, 2017 / Aemetis, Inc. (NASDAQ: AMTX) announced that the company will host a conference call to review the release of its fourth quarter and year-end 2016 earnings report:

Date: Tuesday, March 7, 2017
Time: 11 am Pacific Time (PT)
Live Participant Dial In (Toll Free): (866) 682-6100
Live Participant Dial In (International): (862) 255-5401

Webcast URL: http://www.investorcalendar.com/IC/CEPage.asp?ID=175666

Attendees may submit questions during the Q&A portion of the conference call.

After March 7th, the webcast will be available on the Company’s website (www.aemetis.com) under Investors/Conference Calls. The voice recording will also be available through March 14, 2017 by dialing (Toll Free) 877-481-4010 or (International) 919-882-2331 and entering conference ID number 10130.

About Aemetis

Headquartered in Cupertino, California, Aemetis is an advanced renewable fuels and biochemicals company focused on the acquisition, development and commercialization of innovative technologies that replace traditional petroleum-based products by the conversion of second-generation ethanol and biodiesel plants into advanced biorefineries. Founded in 2006, Aemetis owns and operates a 60 million gallon per year ethanol production facility in California’s Central Valley, near Modesto. Aemetis also owns and operates a 50 million gallon per year renewable chemical and advanced fuel production facility on the East Coast of India producing high quality distilled biodiesel and refined glycerin for customers in India and Europe. Aemetis operates a research and development laboratory at the Maryland Biotech Center, and holds a portfolio of patents and related technology licenses for the production of renewable fuels and biochemicals. For additional information about Aemetis, please visit www.aemetis.com.

SOURCE: Aemetis, Inc.

ReleaseID: 456129